Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

COEP Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Coeptis Therapeutics, Inc.NASDAQ: COEP

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 6.03M shares rose 96.3% year over year, ahead of the -77.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 42.4% from the prior quarter. Over 3 fiscal years it compounded at -33.3% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +96.3% holds above the trailing-twelve-month pace of -77.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
6.03M+42.4% QoQ
Last fiscal yearDec 2025
4.23M+120.0% YoY
LTMMar 2026
4.68M-77.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+96.3%——
1 year+120.0%——
3-year CAGR-33.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
4.23M USD
Year-over-year change
+120.0%
4-year CAGR
+42.7%

Weighted Avg Shares vs competitors

How COEP compares with its peers on the latest reported figures

  • COEP's LTM Mar 2026 weighted avg shares of 4.68M shares is the 8th highest of the 9 companies compared; the peer median is 31.85M shares.
  • Its year-over-year change of -77.3% is the lowest of 9, against a peer median of +75.8%.
  • Over three fiscal years its annual growth of -33.3% compares with a peer median of +20.3%.
COEP Competitors Peer median
Weighted Avg Shares for COEP and competitors
Company Period LTM YoY 3-year CAGR
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
EQEquillium, Inc.LTM Mar 202664.9M +83.3%+39.7%
OTLKOutlook Therapeutics, Inc.LTM Mar 202653.45M +120.6%+48.6%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 202632.45M +9.5%+2.2%
OSTXOS Therapies IncorporatedLTM Mar 202631.25M -31.1%+8.2%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
KPTIKaryopharm Therapeutics Inc.LTM Mar 202614.32M +72.2%+26.1%
COEPCoeptis Therapeutics, Inc.LTM Mar 20264.68M -77.3%-33.3%
CUECue Biopharma, Inc.LTM Mar 20263.74M +79.5%+38.5%
Peer median (excluding COEP) 31.85M+75.8%+20.3%

Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75K0001.36M
Cost of Revenue0000180.63K
Gross Profit75K0001.18M
Gross Margin100.0%———86.7%
Research & Development020.89K6.67M2.33M1.28M
Selling, General & Admin14.12M34.18M13.82M6.72M11.95M
Operating Expenses14.12M34.2M21.49M10.05M14.23M
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
EBITDA(12.81M)(36.35M)(20.12M)(9.38M)(10.41M)
EBITDA Margin-17086.3%———-763.9%
Operating Income(14.05M)(34.2M)(21.49M)(10.05M)(13.04M)
Operating Margin-18727.9%———-956.9%
Interest Income0000116.5K
Interest Expense187.13K218.41K107.69K396.12K642.38K
Other Income / Expenses596.65K(3.38M)224.59K(822.92K)766.31K
Income Before Tax(13.45M)(37.57M)(21.27M)(10.88M)(12.28M)
Pre-Tax Margin-17932.4%———-900.7%
Income Tax Expense00000
Net Income(13.45M)(37.57M)(21.27M)(10.68M)(11.92M)
Net Margin-17932.4%———-874.3%
EPS (Basic)(13.16)(2.87)(0.83)(5.65)(2.81)
EPS (Diluted)(13.16)(2.87)(0.83)(5.65)(2.81)
Weighted Avg Shares1.02M14.3M25.69M1.93M4.23M
Weighted Avg Shares (Diluted)1.02M14.3M25.69M1.93M4.23M

Coeptis Therapeutics, Inc.

NASDAQ:COEP

Intrinsic Alpha fair value

Locked

Current Price

$14.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.